## Mapping the antigenic diversification of SARS-CoV-2

2

- 3 Karlijn van der Straten<sup>1-3</sup>, Denise Guerra<sup>1-2</sup>, Marit J. van Gils<sup>1-2</sup>, Ilja Bontjer<sup>1-2</sup>,
- 4 Tom G. Caniels<sup>1-2</sup>, Hugo D.G. van Willigen<sup>1-2</sup>, Elke Wynberg<sup>4</sup>, Meliawati Poniman<sup>1-2</sup>, Judith A.
- 5 Burger<sup>1-2</sup>, Joey H. Bouhuijs<sup>1-2</sup>, Jacqueline van Rijswijk<sup>1-2</sup>, Wouter Olijhoek<sup>1-2</sup>, Marinus H.
- 6 Liesdek<sup>1-3</sup>, A. H. Ayesha Lavell<sup>2,5</sup>, Brent Appelman<sup>6</sup>, Jonne J. Sikkens<sup>2,5</sup>, Marije K. Bomers<sup>2,5</sup>,
- 7 Alvin X. Han<sup>1-2</sup>, Brooke E. Nichols<sup>1-2,7</sup>, Maria Prins<sup>3,4</sup>, Harry Vennema<sup>8</sup>, Chantal Reusken<sup>8</sup>,
- 8 Menno D. de Jong<sup>1-2</sup>, Godelieve J. de Bree<sup>3</sup>, Colin A. Russell<sup>1-2\*</sup>, Dirk Eggink<sup>1-2,8\*</sup>, Rogier W.
- 9 Sanders 1-2,9\*
- 10
- 11
- 12 <sup>1</sup> Amsterdam UMC location University of Amsterdam, Department of Medical Microbiology
- 13 and Infection prevention, Laboratory of Experimental Virology, Meibergdreef 9, 1105 AZ
- 14 Amsterdam, The Netherlands
- 15 <sup>2</sup> Amsterdam institute for Infection and Immunity, Infectious diseases, Amsterdam, The
- 16 Netherlands
- 17 <sup>3</sup> Amsterdam UMC location University of Amsterdam, Department of Internal Medicine,
- 18 Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
- 19 <sup>4</sup> Department of Infectious Diseases, Public Health Service of Amsterdam, GGD, 1018 WT
- 20 Amsterdam, The Netherlands
- 21 <sup>5</sup> Amsterdam UMC location VU University Amsterdam, Department of Internal Medicine,
- 22 Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
- 23 <sup>6</sup> Amsterdam UMC location University of Amsterdam, Center for Experimental and
- 24 Molecular Medicine, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
- 25 <sup>7</sup> Department of Global Health, Boston University School of Public Health, Boston, USA
- 26 <sup>8</sup> Centre for Infectious Disease Control, National Institute for Public Health and the
- 27 Environment, 3721 MA Bilthoven, The Netherlands
- 28 Department of Microbiology and Immunology, Weill Medical College of Cornell University,
- 29 New York, USA
- 30 \* correspondence to:
- 31 c.a.russell@amsterdamumc.nl, dirk.eggink@rivm.nl, r.w.sanders@amsterdamumc.nl

## Summary

Large-scale vaccination campaigns have prevented countless hospitalizations and deaths due to COVID-19. However, the emergence of SARS-CoV-2 variants that escape from immunity challenges the effectiveness of current vaccines. Given this continuing evolution, an important question is when and how to update SARS-CoV-2 vaccines to antigenically match circulating variants, similar to seasonal influenza viruses where antigenic drift necessitates periodic vaccine updates. Here, we studied SARS-CoV-2 antigenic drift by assessing neutralizing activity against variants-of-concern (VOCs) of a unique set of sera from patients infected with a range of VOCs. Infections with D614G or Alpha strains induced the broadest immunity, while individuals infected with other VOCs had more strain-specific responses. Omicron BA.1 and BA.2 were substantially resistant to neutralization by sera elicited by all other variants. Antigenic cartography revealed that Omicron BA.1 and BA.2 are antigenically most distinct from D614G, associated with immune escape and likely requiring vaccine updates to ensure vaccine effectiveness.

**Keywords:** SARS-CoV-2, variants of concern (VOCs), convalescent, vaccination, neutralization, antibodies, antigenic cartography

## Main text

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

The COVID-19 pandemic, caused by the SARS-CoV-2 virus, represents an enormous threat to human health and a burden to healthcare systems and economies worldwide. The unprecedented rapid development of efficacious vaccines fuelled hope of curtailing this pandemic and permitting a return to a society without societal restrictions. However, genetic drift of SARS-CoV-2 resulted in the emergence of multiple variants of concern (VOCs) with a higher transmissibility compared to the ancestral strain, and that challenge the effectiveness of public health measures, vaccines and/or therapeutics (World Health Organization, 2021). Based on this definition, the WHO designated the Alpha (Pango lineage B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2) and Omicron (B.1.1.529, sublineages BA.1 and BA.2) variants as VOCs. The Alpha, Beta, Gamma and Delta VOCs have approximately 7 to 12 mutations in the Spike protein (S), while Omicron BA.1 with 34 mutations, of which 3 deletions, and BA.2 with 28 mutations, differ substantially more from the ancestral strain (Figure 1A)(World Health Organization, 2021). Approximately half of Omicron's S mutations are located in the Receptor Binding Domain (RBD) and eight mutations in the N-terminal domain (NTD), the two most important antigenic site of S. Indeed, sera from COVID-19 patients infected with the ancestral strain and sera from vaccinees show up to 7-fold and 4-fold reductions in neutralization activity against Beta and Gamma, while 20 to 40-fold reductions are observed against Omicron BA.1 (Caniels et al., 2021; Garcia-Beltran et al., 2021; van Gils et al., 2022; Wilhelm et al., 2021).

However, the precise antigenic relationships between these VOCs are only starting to become clear. Understanding the differences between the serological antibody responses elicited by these variants is important to assess the risk of re-infections after natural infection and breakthrough infections after vaccination. For seasonal influenza viruses, this type of antigenic data is combined with virus genetic and epidemiological data to quantify the evolution of the virus and guide annual updates of the seasonal influenza virus vaccines. Antigenic cartography can be used to visualize antigenic relationships between viral variants (Fonville et al., 2014; Smith et al., 2004) and is routinely used in influenza virus vaccines strain selection. Until recently, antigenic cartography for SARS-CoV-2 has only been applied to cohorts of COVID-19 patients with uncertainty about their history of previous SARS-CoV-2 exposure and COVID-19 vaccinations, and without the usage of Omicron infected human

data (Liu et al., 2021; Mykytyn et al., 2022; Wilks et al., 2022). Here, we studied the (cross-)neutralizing antibody responses in sera from a well-defined population of convalescent individuals with a sequence confirmed, or high likelihood of, primary infection by the D614G, Alpha, Beta, Gamma, Delta or Omicron BA.1 or BA.2 variants and used this data as input for antigenic cartography to map the antigenic evolution of SARS-CoV-2.

We collected and analysed a unique set of serum samples from 66 COVID-19 patients with a PCR-confirmed primary SARS-CoV-2 infection who did not receive any COVID-19 vaccinations. Blood was drawn 3 to 11 weeks after symptom onset (median 40 days, range 24 to 75 days), which corresponds with the peak of the antibody response (Table 1 and Table S1)(Long et al., 2020). In total, n=20 D614G, n=11 Alpha, n=8 Beta, n=4 Gamma, n=11 Delta, n=8 Omicron BA.1 and n=4 Omicron BA.2 infected participants were included. Of these participants, 39 had a sequence-confirmed VOC infection. The other 27 participants met our inclusion criteria of a high likelihood of VOC infection (see STAR Methods section and Table S1), of which 20 participants were assumed to be infected with the D614G strain as they were sampled before the emergence of any VOC in the Netherlands, but after D614G became dominant (Korber et al., 2020).

We assessed the neutralizing capacity of the convalescent sera in a lentiviral-based pseudovirus neutralization assay against the D614G strain, the Alpha, two Beta, the Gamma, Delta and Omicron BA.1 and BA.2 variants (Figure 1A). The two Beta subvariants differ from each other in the NTD, where one Beta subvariant (L242H, R246I) is based on a very early available sequence while the other ( $\Delta$ 242-244) is retrospectively more representative for the predominant circulating strains.

The highest neutralization titres were generally measured against the homologous virus, as might be expected (Figure 1A and Figure S1A). Only the Beta infected participants showed higher cross-neutralization titres against the Gamma variant compared to homologous neutralization, which is in line with other research(Wilks *et al.*, 2022). This might be explained by the shared RBD mutations, as the RBDs of these variants only differ by one amino acid (K417N in Beta *versus* K417T in Gamma). Our analyses suffer somewhat from a disbalance in hospitalized versus non-hospitalized patients between the different VOC groups(Table 1). However, when comparing only non-hospitalized patients which generally have lower antibody levels compared to hospitalized patients, patients infected

with the Alpha variant showed the strongest homologous neutralization (1881 IU/mL, range 1658 to 2103 IU/mL), followed by individuals infected with the Gamma variant (median of 156 IU/mL, range 22 to 761 IU/mL), the D614G strain (median of 90 IU/mL, range 28 to 237 IU/mL) the Delta variant (median of 85 IU/mL, range 10 to 1635 IU/mL), the Omicron BA.2 (median of 64 IU/mL, range 10 to 95 IU/mL) and the Omicron BA.1 variant (median of 23 IU/mL, range 10 to 90 IU/mL) (Figure S1A). By contrast, none of the Beta infected participants showed substantial homologous neutralization against either Beta subvariants (Figure 1A, Figure S2).

Overall, the VOCs differed in their capacity to induce cross-neutralizing antibodies. Individuals infected with the Alpha variant induced the broadest response, followed by D614G strain-infected, Gamma-infected and Delta-infected patients (Figure 1A, Figure 1B and Figure S1B), though there was substantial heterogeneity within all groups. Notably, none of the patients infected with the Beta, Omicron BA.1 or Omicron BA.2 variants showed substantial cross-neutralization activity.

Reductions in neutralizing activity against the two Omicron variants were substantial in all groups (Figure 1A and 1B). Omicron neutralization dropped below the limit of detection ( $10\,IU/mL$  or an  $ID_{50}$  of 100) in 44/66 of the studied individuals for BA.1 and 37/66 for BA.2. The median fold-reduction of Omicron BA.1 neutralization versus homologous neutralization was 9-fold (range 1 to 93-fold) when considering all patients, 10-fold (range 3 to 93-fold) for patients infected with a D614G strain, 52-fold (range 11 to 89-fold) for Alpha, 6-fold (range 1 to 22-fold) for Gamma, and 6-fold (range 1 to 51-fold) for Delta infected patients. The median fold-reduction of Omicron BA.2 neutralization versus homologous neutralization was 5.4-fold (range -3.7 to 134-fold) when considering all patients, 8-fold (range 3 to 47-fold) for patients infected with D614G strain, 68-fold (range 18 to 134-fold) for Alpha, 6-fold (range 1 to 22-fold) for Gamma, and 6-fold (range 1 to 60-fold) for Delta infected patients.

To explore the antigenic relationships between the VOCs, we used the neutralization data to construct a SARS-CoV-2 antigenic map (Figure 2A). In this map, homologous sera tend to cluster around the infecting strain, reflecting that homologous neutralization is dominant. The D614G and Alpha viruses cluster tightly together in the centre of the map, while the Beta (L242H, R246I), Gamma, and Delta variants all lie within 2 antigenic units (1 unit = 2-fold change in neutralization titre) of the D614G strain suggesting a high degree of

antigenic similarity. For influenza viruses, variants are considered to be antigenically similar in case of antigenic distances below 3 antigenic units, i.e. an 8-fold change in neutralization titre, and different when above this threshold(Barr et al., 2014; Prevention, 2021). By analogy, the D614G, Alpha, Beta (L242H, R246I), Gamma and Delta variants belong to one antigenic cluster. Interestingly, the Beta (Δ242-244) subvariant is antigenically more distinct from the D614G strain compared to Beta (L242H, R246I) (e.g. 3 to 4 units), implying that the deletion at region 242-244 has a substantial effect on antigenicity and illustrates the importance of the NTD as target of neutralizing antibodies and/or in modulating antigenicity of other domains by allosteric means. The distance between the main antigenic cluster and Omicron BA.1 and BA.2 variants is more than 4 antigenic units (>16-fold change in neutralization) implying that Omicron BA.1 and BA.2 are the antigenically most distinct SARS-CoV-2 variants (Figure 2A). One caveat is that it is unclear whether 2-fold changes in pseudovirus neutralization titres are directly comparable to 2-fold changes in hemagglutination inhibition assay titres used to define different antigenic clusters of influenza viruses. However, the change in neutralization between Omicron BA.1 and BA.2 and other variants of SARS-CoV-2, including the D614G strain, is striking.

We next used neutralization data from sera of 109 COVID-19 naïve vaccinees receiving either two Moderna (mRNA-1273, n=30), Pfizer/BioNTech (BNT162b2, n=49), or AstraZeneca (AZD1222, n=30) vaccines, which are all based on the ancestral S sequence to generate a second antigenic map (van Gils *et al.*, 2022). This map (Figure 2B) agreed well with the infectee maps (Figure 2A), and corroborated that Omicron BA.1 represents a distinct antigenic variant from viruses currently included in vaccines. Interestingly, while the distributions of sera from recipients of different vaccines overlap, there is a skew of sera of mRNA-1273 vaccinees towards Omicron BA.1, suggesting small differences in antigen stimulation among vaccine formulations considered here.

We have started to define the antigenic SARS-CoV-2 landscape after two years of antigenic drift, which should inform risk assessment of re-infections as well as strain selection for COVID-19 vaccine updates. We can draw several conclusions. First, homologous neutralization was usually stronger than heterologous neutralization. Second, heterologous responses were broadest and most potent in individuals infected with Alpha and D614G strains, while infection with Delta resulted in narrow-specificity responses. In

addition, the individuals infected with the Beta and Omicron BA.1 variant, and to lesser extent Omicron BA.2 infected individuals, developed weak neutralizing responses against any VOC, including the homologous strains, suggesting that the S proteins of Beta and both Omicron variants are less immunogenic compared to the S of other VOCs. Interestingly, the weak homologous and cross-neutralization levels of Beta variant infected individuals are in contrast with the higher titres found by others(Cele et al., 2022; Liu et al., 2021; Rossler et al., 2022; Wilks et al., 2022). It is unlikely that this weak homologous neutralization is caused by a sequence mismatch between the strains causing the infection and the sequence used in our pseudoviruses, as both Beta subvariant pseudoviruses escape homologous neutralization of Beta sera, and the reduction of cross-neutralization of sera elicited by other VOCs against the Beta variants are in line with previous studies (Cele et al., 2022; Liu et al., 2021; Rossler et al., 2022; Wilks et al., 2022). One contributing factor for these low (cross-)neutralization titres by the Beta variant includes cohort specific differences between studies, which is, however, hard to verify due to limited patient characteristic and demographic information available in publications. The weak homologous and crossneutralization of Omicron BA.1 variant infected individuals is in line with other pre-print data(Mykytyn et al., 2022). Third, the D614G and Alpha strains are at the centre of our antigenic map, which supports the use of the current COVID-19 vaccines based on the ancestral strain, in case of circulation of the Alpha, Beta (L242H, R246I), Gamma and Delta variants. Our data suggest that updated vaccines based on the Beta (L242H, R246I) or Delta variants would not have been appreciably more effective than the ancestral virus-based vaccines. However, the substantial reduction of neutralization in all groups against the Beta  $\Delta$ 242-244, but especially against the Omicron variants indicates a high risk of re-infections and vaccine breakthrough cases when exposed to these VOCs. The long antigenic distance between Omicron variants and the preceding variants in the antigenic map indicates that the current high rates of Omicron infections are at least partially associated with immune escape and that a vaccine update is required. While finishing this study, several other efforts to antigenically characterize VOCs became available (Mykytyn et al., 2022; Wilks et al., 2022). Our antigenic cartography is largely in accordance with these other studies.

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

As in the case of seasonal influenza viruses, the prospect of SARS-CoV-2 becoming an endemic virus with recurring outbreaks implies the need for surveillance of antigenic drift and possibly yearly administration of updated vaccines, especially for individuals at risk for

- severe COVID-19. Antigenic cartography efforts such as those presented here, can inform
- 208 future vaccine updates.

209

- 210 Acknowledgements
- 211 We thank all public health services (GGD) in the Netherlands for their help in contacting
- 212 participants. We are also thankful to the study personnel and the participants of the COSCA,
- 213 RECoVERED and the S3-study for their contribution to this research.

214

- 215 Author Contributions
- 216 Conceptualization, K.vdS., D.G., M.J.vG., C.R., C.A.R., D.E., R.W.S.,
- 217 Methodology, K.vdS., D.G., M.J.vG., C.A.R., D.E., R.W.S.,
- 218 Validation, K.vdS., D.G., M.J.vG., I.B.,
- 219 Formal Analysis, K.vdS., A.X.H., B.E.N., C.A.R.,
- 220 Investigation, I.B., M.Po., J.A.B., J.H.B., J.vR., W.O.,
- 221 Resources, K.vdS., I.B., H.D.G.vW., E.W., M.H.L., A.H.A.L., B.A., J.L.S., M.K.B., M.Pr., H.V.,
- 222 C.R., M.D.dJ, G.J.dB,
- 223 Writing original draft, K.vdS., D.G., A.X.H., C.A.R., D.E., R.W.S.,
- Writing review & editing, M.J.vG, I.B., T.G.C., H.D.G.vW., E.W., M.Po., J.A.B., J.H.B.,
- 225 J.vR., W.O., M.H.L., A.H.A.L., B.A., J.J.S., M.K.B., B.E.N., M.Pr., H.V., C.R., M.D.dJ.,
- 226 G.J.dB.
- 227 Visualization, K.vdS., T.G.C., A.X.H., C.A.R., R.W.S.,
- 228 Supervision, C.A.R., D.E., R.W.S.,
- 229 Project administration, K.vdS., D.G.,
- Funding acquisition, J.J.S., M.K.B., A.X.H., M.P., M.D.dJ., G.J.dB., C.A.R., R.W.S.,

231

- 232 Conflicts of interest
- None of the authors have conflicts of interest related to this research.

- 235 Funding
- 236 R.W.S. and C.A.R. are recipients of Vici grants from the Netherlands Organization for
- 237 Scientific Research (NWO no. 91818627 for R.W.S.). C.A.R. and A.X.H. are also supported by
- 238 an ERC Consolidator Award. This work was supported by the NWO ZonMw grant agreement
- 239 no. 10150062010002 to M.D.dJ., and 10430072110003 to G.J. de Bree and the Public Health
- 240 Service of Amsterdam Research & Development grant number 21-14 to M. Prins

(RECoVERED). J.J.S. and M.K.B. are recipients of the NWO grant agreement no. 10430022010023 and 10430022010030.

## Figure legends

Figure 1. SARS-CoV-2 genetic diversity and neutralization. A. Molecular models of SARS-CoV-2 S, highlighting the locations of mutations in the D614G strain (blue), Alpha (green), Beta (yellow), Gamma (orange), Delta (red), Omicron BA.1 (magenta) and Omicron BA.2 (pink) variants. Midpoint neutralization titres against the VOCs in International Units per mL (IU/mL). The individuals are grouped per VOC and plotted accordingly. Median neutralization titres are highlighted while the individual points are depicted with higher transparency. The light grey bar (10 IU/ml) indicates the neutralization cut-off for all strains except Omicron (cut-off 2 IU/mL, dark grey bar). Non-hospitalized patients are indicated with dots and hospitalized patients with triangles. The individuals that were infected with an Alpha strain that also included the E484K mutation are indicated in green squares. The two individuals in the Omicron BA.1 group that may have been infected with BA.2 instead of BA.1 are indicated in magenta diamonds (see also Table S1). The homologous neutralization is highlighted using a light blue bar. The Wilcoxon signed rank test with Benjamini Hochberg correction was used to compare cross-neutralization titres with the homologous neutralization (see Table S3A for exact p-values). Only statistically significant differences are indicated. \* = p< 0.005, \*\* = p<0.01, \*\*\*\* = p<0.0001. **B.** Spider plot of the median neutralization titre (IU/mL) of each group against all VOCs. A cut-off of 10 IU/mL is used for all strains.

Figure 2. SARS-CoV-2 antigenic cartography. A. Antigenic map of SARS-CoV-2 VOCs based on convalescent SARS-CoV-2 infection sera. SARS-CoV-2 variants are shown as circles and sera are indicated as squares. Each square corresponds to sera of one individual and is coloured by the infecting SARS-CoV-2 variant. Both axes of the map are antigenic distance and each grid square (1 antigenic unit) represents a two-fold change in neutralization titre. The distance between points in the map can be interpreted as a measure of antigenic similarity, where the points more closely together show higher cross-neutralization and are therefore antigenically more similar. The left panel included both Beta subvariants used in this study. The right panel is without the Beta ( $\Delta 242-244$ ) subvariant **B.** Antigenic map of

273	SARS-CoV-2 VOCs based on post-vaccination sera from individuals without prior SARS-CoV-2				
274	infections. Each serum is coloured by the vaccine that individual received.				
275					
276	Table 1. Sociodemographics and	clinical characteristics	<b>s.</b> A summary of the convalescent		
277	SARS-CoV-2 patients included in	this study. Table S1	contains a more comprehensive		
278	overview	per	individual.		

# **KEY RESOURCES TABLE**

REAGENT or RESOURCE	SOURCE	IDENTIFIER
DMEM media	Gibco	Cat#: 11966025
Opti-MEM I reduced serum media	Gibco	Cat#: 15392402
Phosphate-buffered saline (PBS)	Gibco	Cat#: 15326239
Bacterial and virus strains		
Chemically competent DH5 $\alpha$ Escherichia coli	Thermo Fisher	Cat#: 12879416
	Scientific	
Biological samples		
Human sera, convalescent SARS-Cov-2	This study	N/A
Human sera, post-COVID-19 vaccination	(van Gils <i>et al.,</i> 2022)	N/A
Chemicals, peptides, and recombinant proteins		
FastDigest Sacl	Thermo Fisher	Cat#: 10324720
	Scientific	
FastDigest Apal	Thermo Fisher	Cat#: 10450280
	Scientific	
Polyethylenimine hydrochloride (PEI) MAX	PolySciences	Cat#: 24765-1
Trypsin-EDTA	Gibco	Cat#: 25-200-056
GlutaMAX	Gibco	Cat#: 35050061
Glycylglycine, 99+%	Acros	Cat#: 120141000
	Organics/Thermo Scientific	
Magnesium sulfate heptahydrate, 99.5%, for analysis,	Acros Organics/	Cat#: AC21311500
Thermo Scientific™	Thermo Scientific	
EGTA (ethylene glycol bis(2-aminoethyl ether)- N,N,N',N'-tetraacetic acid) ≥97%, Ultra Pure Grade	VWR	Cat#: 0732-100G
Triton™ X-100 (Electrophoresis), Fisher BioReagents™	Fisher BioReagents	Cat#: BP151-500
Poly-L-Lysine Hydrobromide	Sigma-Aldrich	Cat#: P1399
Critical commercial assays		
Gibson Assembly	New England BioLabs	E5510S
QuikChange Site-Directed Mutagenesis Kit	Agilent Technologies	Cat#: 200523
Experimental models: Cell lines		
HEK293T cells	American Type	CRL-11268
	Culture Collection	
HEK-293T-hACE2	(Schmidt et al., 2020)	RRID:CVCL_A7UK
Oligonucleotides		
SARS-CoV-2 D614G spike gene fragment	Integrated DNA	GenBank:MT449663.1
	Technologies	Mutations in this paper
SARS-CoV-2 Alpha spike gene fragment	Integrated DNA	GenBank:MT449663.1
	Technologies	Mutations in this paper
SARS-CoV-2 Beta spike gene fragment	Integrated DNA	GenBank:MT449663.1
	Technologies	Mutations in this paper

SARS-CoV-2 Gamma spike gene fragment	Integrated DNA	GenBank:MT449663.1
	Technologies	Mutations in this paper
SARS-CoV-2 Delta spike gene fragment	Integrated DNA	GenBank:MT449663.1
	Technologies	Mutations in this paper
SARS-CoV-2 Omicron BA.1 spike gene fragment	Integrated DNA	GenBank:MT449663.1
	Technologies	Mutations in this paper
SARS-CoV-2 Omicron BA.2 spike gene fragments	Integrated DNA	GenBank:MT449663.1
	Technologies	Mutations in this paper
Recombinant DNA		
pCR3 SARS-CoV-2– $S_{\Delta 19}$ expression plasmid	GenBank	ID: MT449663.1
pHIV-1 <sub>NL43</sub> ΔEnv-NanoLuc reporter virus plasmid	(Schmidt <i>et al.</i> , 2020)	
Software and algorithms		
ACMACS antigenic cartography software	https://acmacs-	N/A
	web.antigenic-	
	cartography.org	
GraphPad Prism 8.3.0	GraphPad	RRID:SCR_002798;
		http://www.graphpad.co
		<u>m/</u>
Microsoft Excel	Microsoft	RRID:SCR_016137;
		https://www.microsoft.c
		om/en-gb/
Other		
Other Nano-Glo Luciferase Assay System	Promega	Cat#: N1130

282283

284

285

286

287

288

289

290

291

292

293

#### **RESOURCE AVAILABILITY**

#### Lead contact

Further information and requests for resources and reagents should be directed to and will

be fulfilled by the lead contact, Rogier W. Sanders (<u>r.w.sanders@amsterdamumc.nl</u>)

## Materials availability

This study did not generate new unique reagents.

## Data and code availability

Neutralisation and patient characteristic data have been deposited as supplementary tables within this manuscript (Table S1 and Table S2) and are publicly available as of the date of publication. Other accession numbers are listed in the key resources table. This paper does not report original code. Any additional information required to reanalyse the data reported in this paper is available from the lead contact upon request.

294295

296

297

#### **EXPERIMETNAL MODEL AND SUBJECT DETAILS**

## Study population

66 adults (aged 18 to 76) with a PCR proven primary SARS-CoV-2 infection were included in the COSCA-study (NL 73281.018.20) or the RECOVERED study (NL73759.018.20) between June 2020 and April 2022 at Amsterdam UMC and via the Dutch national SARS-CoV-2 sequence surveillance program as described previously(Grobben et al., 2021; Wynberg et al., 2021). In short, 3-11 weeks after symptom onset, blood, patient demographics, time between symptom onset and sampling, and admission status were collected (Table 1 and Table S1). The diagnostic oropharyngeal swab was available for 39 participants and were used to determine the SARS-CoV-2 strain causing the infection. The remaining 27 SARS-CoV-2 infected participants fell within the following inclusion criteria: (1) ≥95% of circulating strains at time of symptom onset belonged the suspected VOC of infection or (2) ≥75% of circulating strains at the time of symptom onset belonged the suspected VOC of infection AND a household member had a concurrent sequence confirmed infection with that particular VOC. Prevalence data of CoVariants.org and the National Institute for Public Health and the Environment were used to determine the current prevalence of a VOC (CoVariants, 2022; Rijksinstituut voor Volksgezondheid en Milieu (RIVM)). Most individuals of which no sequence confirmation of the infected strain was available, were presumed to be infected with de D614G variant (n=20) as they were sampled before the emergence of any VOC in the Netherlands and after D614G became predominant in the Netherlands(Korber et al., 2020). More details about the remaining n=7 individuals can be found in the Table S1. The two Omicron individuals that may have been infected by either BA.1 or BA.2 are indicated as diamonds in all graphs. Two of the individuals infected with an Alpha strain harbouring the E484K mutation are indicated as squares in all graphs.

Neutralization data on COVID-19 naive vaccinee sera were kindly provided by the S3-study of the Amsterdam UMC, The Netherlands(NL73478.029.20) (van Gils *et al.*, 2022). In short, post-vaccination sera was obtained approximately four weeks after the second doses of either Moderna (mRNA-1273), Pfizer/BioNTech (BNT162b2), or AstraZeneca (AZD1222). Post-vaccination serum after Janssen (Ad26.COV2.S) were excluded from analysis because they did not have enough non-threshold titres to be included in the map.

All above mentioned studies were conducted at the Amsterdam University Medical Centres, the Netherlands, and approved by the local ethical committees. All individuals provided written informed consent before participating.

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

## Pseudovirus design

330

331 The D614G strain and the Alpha pseudovirus constructs contained the following mutations: 332 D614G in D614G strain; deletion (Δ) of H69, V70 and Y144, N501Y, A570D, D614G, P681H, 333 T716I, S982A, and D1118H in Alpha. The two Beta subvariants differ from each other in the 334 NTD region 242-246, where one Beta subvariant (L242H, R246I) is based on a very early 335 available sequence while the other ( $\Delta 242-244$ ) is retrospectively more representative for 336 the predominant circulating strains. These two Beta pseudovirus constructs contain 337 therefore the following mutations: L18F, D80A, D215G, L242H, R246I, K417N, E484K, N501Y, 338 D614G, and A701V in Beta (L242H, R246I); L18F, D80A, D215G, Δ242-244, K417N, E484K, 339 N501Y, D614G, and A701V in Beta (Δ242-244). Only the D614G infected individuals showed 340 statistically significant reduced neutralization against the Beta ( $\Delta 242-244$ ) subvariant 341 compared to the Beta (L242H, R246I) subvariant (Figure S2). The Gamma pseudovirus 342 constructs contained the following mutations: L18F, T20N, P26S, D138Y, R190S, K417T, 343 E484K, N501Y, D614G, H655Y, and T1027I in Gamma; This Gamma pseudovirus construct 344 differs from the predominant strain in that it lacks a V1176F back bone mutation. However, 345 it is not likely that this mutation, positioned at the S2 domain of the S, will affect escape of 346 neutralization substantially. The Delta and Omicron BA.1 and BA.2 pseudovirus constructs 347 contained the following mutations: T19R, G142D, E156G, Δ157-158, L452R, T478K, D614G, 348 P681R and D950N in Delta; A67V, Δ69-70, T95I, G142D, Δ143-145, Δ211, L212I, ins214EPE, 349 G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493K, G496S, 350 Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, 351 N969K, L981F in Omicron BA.1; and T19I, L24S, Δ125/127, G142D, V213G, G339D, S371F, 352 S373P, S375F, T376A, D405N, R408S, K417N, N440K, S477N, T478K, E484A, Q493R, Q498R, 353 N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K in Omicron 354 BA.2. The Omicron BA.1 strain used here harbors a Q493K mutation, while the predominant 355 Omicron BA.1 harbors a Q493R mutation. This mutation did not impacted neutralization of 356 several monoclonal SARS-CoV-2 antibodies tested (data not shown). The spike constructs 357 were ordered as gBlock gene fragments (Integrated DNA Technologies) and cloned SacI and 358 Apal in the pCR3 SARS-CoV-2−S<sub>∆19</sub> expression plasmid (GenBank: MT449663.1) using Gibson 359 Assembly (Thermo Fisher Scientific). The pseudovirus constructs were made using the 360 QuikChange Site-Directed Mutagenesis Kit (Agilent Technologies) and verified by using 361 Sanger sequencing. Pseudoviruses were procedures by cotransfecting HEK293T cells

(American Type Culture Collection, CRL-11268) with the pCR3 SARS-CoV-2- $S_{\Delta19}$  expression plasmid and the pHIV- $1_{NL43}$   $\Delta$ Env-NanoLuc reporter virus plasmid. Transfection takes place in cell culture medium (DMEM), supplemented with 10% fetal bovine serum, penicillin (100 U/ml), streptomycin (100 g/ml). Medium is refreshed once 6-8 hours after transfection. 48 hours after the transfection, cell supernatants containing the pseudovirus were harvested and stored at -80 °C until further use.

367368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

362

363

364

365

366

## **METHOD DETAILS**

## SARS-CoV-2 pseudovirus neutralization assay

The pseudovirus neutralization assay was performed as described previously (Caniels et al., 2021). Shortly, HEK293T/ACE2 cells were kindly provided by P. Bieniasz(Schmidt et al., 2020) were seeded at a density of 20,000 cells per well in a 96-well plate coated with poly-lysine (50 ug/ml) 1 day before the start of the neutralization assay. The next day, heat-inactivated sera samples were in triplicate serial diluted in threefold steps, starting at 1:20 dilution to test for Omicron BA.1 and BA.2 pseudovirus neutralization and 1:100 for all the other variants. Sera was diluted in cell culture medium (DMEM), supplemented with 10% fetal bovine serum, penicillin (100 U/ml), streptomycin (100 g/ml), and GlutaMAX (Gibco), mixed in a 1:1 ratio with pseudovirus, and incubated for 1 hour at 37°C. These mixtures were then added to the cells in a 1:1 ratio and incubated for 48 hours at 37°C, and lysis buffer was added. The luciferase activity in cell lysates was measured using the Nano-Glo Luciferase Assay System (Promega) and GloMax system (Turner BioSystems). Relative luminescence units were normalized to those from cells infected with SARS-CoV-2 pseudovirus in the absence of sera. The inhibitory neutralization titres (ID<sub>50</sub>) were determined as the serum dilution at which infectivity was inhibited by 50%, using a nonlinear regression curve fit (GraphPad Prism software version 8.3). The International Standard for anti-SARS-CoV-2 immunoglobulins provided by the WHO(Kristiansen et al., 2021) were used to convert the ID<sub>50</sub> values into International Units per milliliters (IU/mL). Samples with IU/mL titres <10 were defined as having undetectable neutralization against the D614G, Alpha, Beta, Gamma and Delta variant. For Omicron BA.1 and BA.2 neutralization, the start-dilution of 1:20 enables a cut-off of <2 IU/mL for all samples except for some Alpha infected individuals. A limited amount of sera was available from the Alpha infected individuals, resulting in a start dilution of 1:100 of n=7 samples against all variants including Omicron BA.1 and BA.2.

Neutralization data points of two Alpha infected individuals against BA.1 and BA.2 were excluded from Figure 1A because a neutralization titres <10IU/mL (Table S2). This exclusion did not impact the statistics as written below because a general cut-off of <10IU/mL were used for neutralization against any variant, including Omicron BA.1 and BA.2.

## Antigenic cartography

Antigenic maps were constructed as previously described (Fonville *et al.*, 2014; Smith *et al.*, 2004) using the antigenic cartography software from <a href="https://acmacs-web.antigenic-cartography.org">https://acmacs-web.antigenic-cartography.org</a>. In brief, this approach to antigenic mapping uses multidimensional scaling to position antigens (viruses) and sera in a map to represent their antigenic relationships. The maps here relied on the SARS-CoV-2 post-infection serology data and post-vaccination serology data shown in Figure 1A and Table S2. The positions of antigens and sera were optimized in the map to minimise the error between the target distances set by the observed pairwise virus-serum combinations in the pseudovirus assay described above and the resulting computationally derived map. Maps were constructed in 2, 3, 4, and 5 dimensions to investigate the dimensionality of the antigenic relationships. Both the convalescent (Figure 2A) and post-vaccination datasets (Figure 2B) were strongly two-dimensional with only small improvements in residual mean squared error of the maps as map dimensionality increased.

## **QUANTIFICATION AND STATISTICAL ANALYSIS**

Data visualization and statistical analyses were performed in GraphPad Prism software (version 8.3). Spider plots (Figure 1B) were made in Excel 2016. The antigenic maps were produced using the antigenic cartography software mentioned above. Wilcoxon signed rank test with Benjamini Hochberg correction was used to compare cross-neutralization titres with the homologous neutralization (Figure 1A). Mann-Whitney test was used for non-paired group comparisons (Figure S1). All statistics mentioned here were performed by using a general neutralization cut-off of 10IU/mL against any variant of SARS-CoV-2.

#### References:

- Barr, I.G., Russell, C., Besselaar, T.G., Cox, N.J., Daniels, R.S., Donis, R., Engelhardt, O.G.,
- Grohmann, G., Itamura, S., Kelso, A., et al. (2014). WHO recommendations for the viruses
- 426 used in the 2013-2014 Northern Hemisphere influenza vaccine: Epidemiology, antigenic and

- 427 genetic characteristics of influenza A(H1N1)pdm09, A(H3N2) and B influenza viruses
- 428 collected from October 2012 to January 2013. Vaccine 32, 4713-4725.
- 429 10.1016/j.vaccine.2014.02.014.
- 430 Caniels, T.G., Bontjer, I., van der Straten, K., Poniman, M., Burger, J.A., Appelman, B.,
- 431 Lavell, A.H.A., Oomen, M., Godeke, G.J., Valle, C., et al. (2021). Emerging SARS-CoV-2
- 432 variants of concern evade humoral immune responses from infection and vaccination. Sci
- 433 Adv 7, eabj5365. 10.1126/sciadv.abj5365.
- 434 Cele, S., Karim, F., Lustig, G., San, J.E., Hermanus, T., Tegally, H., Snyman, J., Moyo-
- Gwete, T., Wilkinson, E., Bernstein, M., et al. (2022). SARS-CoV-2 prolonged infection
- 436 during advanced HIV disease evolves extensive immune escape. Cell Host Microbe 30, 154-
- 437 162 e155. 10.1016/j.chom.2022.01.005.
- 438 CoVariants (2022). Overview of Variants in Countries. https://covariants.org/per-country.
- 439 Fonville, J.M., Wilks, S.H., James, S.L., Fox, A., Ventresca, M., Aban, M., Xue, L., Jones,
- 440 T.C., Le, N.M.H., Pham, Q.T., et al. (2014). Antibody landscapes after influenza virus
- 441 infection or vaccination. Science 346, 996-1000. 10.1126/science.1256427.
- 442 Garcia-Beltran, W.F., St Denis, K.J., Hoelzemer, A., Lam, E.C., Nitido, A.D., Sheehan, M.L.,
- Berrios, C., Ofoman, O., Chang, C.C., Hauser, B.M., et al. (2021). mRNA-based COVID-19
- 444 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant.
- 445 medRxiv, 2021.2012.2014.21267755. 10.1101/2021.12.14.21267755.
- 446 Grobben, M., van der Straten, K., Brouwer, P.J., Brinkkemper, M., Maisonnasse, P.,
- Dereuddre-Bosquet, N., Appelman, B., Lavell, A.A., van Vught, L.A., Burger, J.A., et al.
- 448 (2021). Cross-reactive antibodies after SARS-CoV-2 infection and vaccination. Elife 10,
- 449 2021.2005.2026.21256092. 10.7554/eLife.70330.
- 450 Korber, B., Fischer, W.M., Gnanakaran, S., Yoon, H., Theiler, J., Abfalterer, W., Hengartner,
- 451 N., Giorgi, E.E., Bhattacharya, T., Foley, B., et al. (2020). Tracking Changes in SARS-CoV-2
- 452 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. Cell 182, 812-827
- 453 e819. 10.1016/j.cell.2020.06.043.
- Kristiansen, P.A., Page, M., Bernasconi, V., Mattiuzzo, G., Dull, P., Makar, K., Plotkin, S.,
- and Knezevic, I. (2021). WHO International Standard for anti-SARS-CoV-2 immunoglobulin.
- 456 Lancet 397, 1347-1348. 10.1016/S0140-6736(21)00527-4.
- Liu, C., Ginn, H.M., Dejnirattisai, W., Supasa, P., Wang, B., Tuekprakhon, A., Nutalai, R.,
- 458 Zhou, D., Mentzer, A.J., Zhao, Y., et al. (2021). Reduced neutralization of SARS-CoV-2
- 459 B.1.617 by vaccine and convalescent serum. Cell 184, 4220-4236 e4213.
- 460 10.1016/j.cell.2021.06.020.
- 461 Long, Q.X., Liu, B.Z., Deng, H.J., Wu, G.C., Deng, K., Chen, Y.K., Liao, P., Qiu, J.F., Lin, Y.,
- 462 Cai, X.F., et al. (2020). Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat
- 463 Med 26, 845-848. 10.1038/s41591-020-0897-1.
- 464 Mykytyn, A.Z., Rissmann, M., Kok, A., Rosu, M.E., Schipper, D., Breugem, T.I., van den
- 465 Doel, P.B., Chandler, F., Bestebroer, T., de Wit, M., et al. (2022). Omicron BA.1 and BA.2
- 466 are antigenically distinct SARS-CoV-2 variants. bioRxiv, 2022.2002.2023.481644.
- 467 10.1101/2022.02.23.481644.
- 468 Prevention, C.o.D.C.a. (2021). Antigenic Characterization.
- 469 <a href="https://www.cdc.gov/flu/about/professionals/antigenic.htm">https://www.cdc.gov/flu/about/professionals/antigenic.htm</a>.
- 470 Rijksinstituut voor Volksgezondheid en Milieu (RIVM). Resultaten kiemsurveillance.
- 471 https://www.rivm.nl/sites/default/files/2022-
- 472 04/Kiemsurveillance%2020220401%20tabel%20NL.pdf.
- 473 Rossler, A., Riepler, L., Bante, D., von Laer, D., and Kimpel, J. (2022). SARS-CoV-2
- 474 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons. N
- 475 Engl J Med 386, 698-700. 10.1056/NEJMc2119236.
- 476 Schmidt, F., Weisblum, Y., Muecksch, F., Hoffmann, H.H., Michailidis, E., Lorenzi, J.C.C.,
- 477 Mendoza, P., Rutkowska, M., Bednarski, E., Gaebler, C., et al. (2020). Measuring SARS-
- 478 CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. J Exp Med
- 479 *217*. 10.1084/jem.20201181.

- 480 Smith, D.J., Lapedes, A.S., de Jong, J.C., Bestebroer, T.M., Rimmelzwaan, G.F., Osterhaus,
- 481 A.D., and Fouchier, R.A. (2004). Mapping the antigenic and genetic evolution of influenza
- 482 virus. Science 305, 371-376. 10.1126/science.1097211.
- van Gils, M.J., Lavell, A., van der Straten, K., Appelman, B., Bontjer, I., Poniman, M., Burger,
- J.A., Oomen, M., Bouhuijs, J.H., van Vught, L.A., et al. (2022). Antibody responses against
- 485 SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care
- workers in the Netherlands: A prospective cohort study. PLOS Medicine 19, e1003991.
- 487 10.1371/journal.pmed.1003991.
- Wilhelm, A., Widera, M., Grikscheit, K., Toptan, T., Schenk, B., Pallas, C., Metzler, M.,
- 489 Kohmer, N., Hoehl, S., Helfritz, F.A., et al. (2021). Reduced Neutralization of SARS-CoV-2
- 490 Omicron Variant by Vaccine Sera and monoclonal antibodies. medRxiv,
- 491 2021.2012.2007.21267432. 10.1101/2021.12.07.21267432.
- Wilks, S.H., Mühlemann, B., Shen, X., Türeli, S., LeGresley, E.B., Netzl, A., Caniza, M.A.,
- 493 Chacaltana-Huarcaya, J.N., Daniell, X., Datto, M.B., et al. (2022). Mapping SARS-CoV-2
- 494 antigenic relationships and serological responses. bioRxiv, 2022.2001.2028.477987.
- 495 10.1101/2022.01.28.477987.
- 496 World Health Organization (2021). Tracking SARS-CoV-2 variants
- 497 <a href="https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/">https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/</a>.
- 498 Wynberg, E., van Willigen, H.D.G., Dijkstra, M., Boyd, A., Kootstra, N.A., van den Aardweg,
- 499 J.G., van Gils, M.J., Matser, A., de Wit, M.R., Leenstra, T., et al. (2021). Evolution of COVID-
- 500 19 symptoms during the first 12 months after illness onset. Clin Infect Dis.
- 501 10.1093/cid/ciab759.

Fig.1 A







Fig. 2A









Variant of concern	N= (%)	Age (years) median (range)	Male	Hospital admission	Sequence confirmed	Time since symptom onset (days) median (range)
D614G	20 (30%)	53 (22-74)	9 (45%)	9 (45%)	0 (0%)	38 (30-45)
Alpha	11 (17%)	48 (25-76)	6 (55%)	9 (82%)	11 (100%)	39 (24-58)
Alpha + E484K	2/11	62 (48-76)	0	2/2	2/2	41 (24-58)
Beta	8 (12%)	41 (18-53)	3 (38%)	0	7 (88%)	39 (30-63)
Gamma	4 (6%)	35 (27-10)	2 (50%)	0	4 (100%)	40 (38-55)
Delta	11 (17%)	31 (19-63)	6 (55%)	1 (9%)	10 (91%)	46 (36-52)
Omicron BA.1	8 (12%)	31 (21-45)	4 (50%)	0	3 (38%)	44 (25-75)
Omicron BA.2	4 (6%)	51 (31-55)	4 (100%)	0	4 (100%)	40 (39-41)
Total	66	41 (18-76)	34 (52%)	21 (32%)	39 (59%)	40 (24-75)

Table 1. Sociode mographics and clinical characteristics